Clinical Trials Browser

Approved for marketing × adagrasib × 1 year × Clear all

NCT05162443 2025-08-26

Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

Approved for marketing

Neoplasm Metastasis, Neoplasms